- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/515 - Facteur angiogéniqueAngiogénine
Détention brevets de la classe C07K 14/515
Brevets de cette classe: 245
Historique des publications depuis 10 ans
|
22
|
24
|
15
|
20
|
14
|
12
|
13
|
10
|
7
|
3
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Novartis AG | 10251 |
17 |
| Modernatx, Inc. | 1292 |
16 |
| Regeneron Pharmaceuticals, Inc. | 4727 |
8 |
| NAIDU, L.P., Satyanarayan Naidu, a United States citizen, and Smita Naidu, a United States citizen | 33 |
7 |
| The Regents of the University of California | 20778 |
6 |
| Retinal Solutions LLC | 15 |
6 |
| Vasomune Therapeutics Inc. | 8 |
6 |
| Agriculture Victoria Services Pty Ltd | 158 |
4 |
| Askgene Pharma, Inc. | 52 |
4 |
| Murray Goulburn Co-operative Co. Limited | 17 |
4 |
| Ottawa Hospital Research Institute | 116 |
4 |
| Sunnybrook Research Institute | 271 |
4 |
| Verve Therapeutics, Inc. | 43 |
4 |
| Samsung Electronics Co., Ltd. | 157946 |
3 |
| Amgen Inc. | 4429 |
3 |
| Northwestern University | 3546 |
3 |
| California Northstate College of Pharmacy, LLC | 21 |
3 |
| Children's Medical Center Corporation | 1957 |
3 |
| Chugh, Sumant S. | 6 |
3 |
| Pieris Pharmaceuticals GmbH | 90 |
3 |
| Autres propriétaires | 134 |